UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open‐label, prospective and randomised clinical trial

Alimentary pharmacology & therapeutics, 2017-07, Vol.46 (2), p.142-149

2017

Volltextzugriff (PDF)

Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study

Alimentary Pharmacology & Therapeutics (Suppl), 2018-04, Vol.47 (7), p.906-912

2018

Volltextzugriff (PDF)

Fetal death in utero and miscarriage in a patient with Crohn's disease under therapy with ustekinumab: case-report and review of the literature

BMC gastroenterology, 2017-06, Vol.17 (1), p.80-80, Article 80

2017

Volltextzugriff (PDF)

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2016-04, Vol.10 (4), p.395-401

2016

Volltextzugriff (PDF)

One‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study

Alimentary Pharmacology & Therapeutics (Suppl), 2017-08, Vol.46 (3), p.310-321

2017

Volltextzugriff (PDF)

What dermatologists should know about faecal calprotectin to allow adequate interpretation of the results in clinical practice

Clinical and experimental dermatology, 2021-06, Vol.46 (4), p.742-743

2021

Volltextzugriff (PDF)

Letter: thiopurines ‐ is less really more? Authors’ reply

Alimentary pharmacology & therapeutics, 2018-01, Vol.47 (1), p.150-150

2018

Volltextzugriff (PDF)

Impact of mucosal healing on long‐term outcomes in ulcerative colitis treated with infliximab: a multicenter experience

Alimentary Pharmacology & Therapeutics (Suppl), 2013-05, Vol.37 (10), p.998-1004

2013

Volltextzugriff (PDF)

Spécificité des stratégies de coping des patients en rémission de la maladie de Crohn : une étude qualitative

Pratiques psychologiques, 2022-03, Vol.28 (1), p.17-27

2022

Volltextzugriff (PDF)

Predictive Models of Therapeutic Response to Vedolizumab: A Novel Step into Personalized Medicine in Crohn's Disease?

Inflammatory bowel diseases, 2018-05, Vol.24 (6), p.1193-1195

2018

Volltextzugriff (PDF)

Intestinal Conventional Ultrasonography, Contrast-Enhanced Ultrasonography and Magnetic Resonance Enterography in Assessment of Crohn’s Disease Activity: A Comparison with Surgical Histopathology Analysis

Digestive diseases and sciences, 2022-06, Vol.67 (6), p.2492-2502

2022

Volltextzugriff (PDF)

Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study

Alimentary Pharmacology & Therapeutics (Suppl), 2017-12, Vol.46 (11-12), p.1077-1084

2017

Volltextzugriff (PDF)

Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study

Journal of Crohn's and colitis, 2022-11, Vol.16 (10), p.1523-1530

2022

Volltextzugriff (PDF)

P465 Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i439-i439

2022

Volltextzugriff (PDF)

Endoscopic Detection of Small Bowel Dysplasia and Adenocarcinoma in Crohn's Disease: A Prospective Cohort-Study in High-Risk Patients

Journal of Crohn's and colitis, 2017-01, Vol.11 (1), p.47-52

2017

Volltextzugriff (PDF)

P679 Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1290-i1290

2024

Volltextzugriff (PDF)

P927 Long-term outcomes of risankizumab in Crohn’s disease: a multicenter GETAID Study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1686-i1686

2024

Volltextzugriff (PDF)

P1071 Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1925-i1925

2024

Volltextzugriff (PDF)

P857 Effectiveness and safety of subcutaneous infliximab in perianal Crohn's disease: a multicentre cohort study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1587-i1587

2024

Volltextzugriff (PDF)

A challenging case of multiple splenic and pancreatic lesions in a patient with Crohn's disease

Gut, 2016-02, Vol.65 (2), p.295-295

2016

Volltextzugriff (PDF)

How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study

Journal of Crohn's and colitis, 2022-08, Vol.16 (8), p.1202-1210

2022

Volltextzugriff (PDF)

Segmental Colectomy for Ulcerative Colitis: Is There a Place in Selected Patients Without Active Colitis? An International Multicentric Retrospective Study in 72 Patients

Journal of Crohn's and colitis, 2020-12, Vol.14 (12), p.1687-1692

2020

Volltextzugriff (PDF)

DOP79 Promising efficacy of biologicals and small molecules for microscopic colitis: results from a large real-life multicenter cohort

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i219-i221

2024

Volltextzugriff (PDF)

Association of Anti-glycan Antibodies and Inflammatory Bowel Disease Course

Journal of Crohn's and colitis, 2015-06, Vol.9 (6), p.445-451

2015

Volltextzugriff (PDF)

Defining and Assessing the Reproducibility of Crohn’s Disease Endoscopic Lesions: A Delphi-like Method from the GETAID

Journal of Crohn's and colitis, 2021-06, Vol.15 (6), p.1000-1008

2021

Volltextzugriff (PDF)

1 – 25 von 814

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(631)
Mit Volltextzugriff
(687)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(5)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open‐label, prospective and randomised clinical trial

Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study

Fetal death in utero and miscarriage in a patient with Crohn's disease under therapy with ustekinumab: case-report and review of the literature

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

One‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study

What dermatologists should know about faecal calprotectin to allow adequate interpretation of the results in clinical practice

Letter: thiopurines ‐ is less really more? Authors’ reply

Impact of mucosal healing on long‐term outcomes in ulcerative colitis treated with infliximab: a multicenter experience

Spécificité des stratégies de coping des patients en rémission de la maladie de Crohn : une étude qualitative

Predictive Models of Therapeutic Response to Vedolizumab: A Novel Step into Personalized Medicine in Crohn's Disease?

Intestinal Conventional Ultrasonography, Contrast-Enhanced Ultrasonography and Magnetic Resonance Enterography in Assessment of Crohn’s Disease Activity: A Comparison with Surgical Histopathology Analysis

Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study

Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study

P465 Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?

Endoscopic Detection of Small Bowel Dysplasia and Adenocarcinoma in Crohn's Disease: A Prospective Cohort-Study in High-Risk Patients

P679 Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial

P927 Long-term outcomes of risankizumab in Crohn’s disease: a multicenter GETAID Study

P1071 Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID

P857 Effectiveness and safety of subcutaneous infliximab in perianal Crohn's disease: a multicentre cohort study

A challenging case of multiple splenic and pancreatic lesions in a patient with Crohn's disease

How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study

Segmental Colectomy for Ulcerative Colitis: Is There a Place in Selected Patients Without Active Colitis? An International Multicentric Retrospective Study in 72 Patients

DOP79 Promising efficacy of biologicals and small molecules for microscopic colitis: results from a large real-life multicenter cohort

Association of Anti-glycan Antibodies and Inflammatory Bowel Disease Course

Defining and Assessing the Reproducibility of Crohn’s Disease Endoscopic Lesions: A Delphi-like Method from the GETAID

Suchergebnisse filtern